North Carolina Medicaid does cover Wegovy. As of December 12, 2025, Wegovy is listed as a Preferred Product on the NC Medicaid Preferred Drug List for weight management, meaning it is the first GLP-1 the program will approve for obesity treatment. Coverage requires prior authorization from your prescriber, and you have to meet specific clinical criteria based on your BMI and, in some cases, other health conditions.
The policy applies to both NC Medicaid Direct (fee-for-service) and NC Medicaid Managed Care, and the same clinical criteria govern prior authorization in both.
Who Qualifies for Wegovy Coverage
Eligibility depends on age. The governing document is the NC Medicaid Outpatient Pharmacy Prior Approval Criteria for GLP-1s for Weight Management, effective August 1, 2024.
Adults 18 and Older
An adult beneficiary must meet one of these thresholds:
- BMI of 30 or higher, or
- BMI of 27 or higher with at least one weight-related comorbidity, such as hypertension, type 2 diabetes, obstructive sleep apnea, cardiovascular disease, or dyslipidemia, or
- Age 45 or older with a BMI of 27 or higher and established cardiovascular disease (a history of heart attack, stroke, or symptomatic peripheral artery disease).
Adolescents Ages 12 to 17
An adolescent qualifies with any of the following:
- BMI at or above the 95th percentile for age and sex,
- BMI of 30 or higher, or
- BMI at or above the 85th percentile for age and sex with at least one severe weight-related comorbidity or risk factor.
For beneficiaries under 21, federal EPSDT rules can allow coverage that goes beyond the standard service limitations when a provider documents medical necessity. A prior authorization request is still required.
What Your Prescriber Has To Submit
The prior authorization request comes from your provider, not from you, and it has to include specific documentation regardless of the patient’s age:
- Baseline weight and BMI measured within 45 days of submission.
- Proof that the patient is participating in structured nutrition counseling and physical activity, unless clinically inappropriate.
- Confirmation that the patient has no FDA-labeled contraindications, including pregnancy, breastfeeding, a history of medullary thyroid cancer, or multiple endocrine neoplasia type 2.
- Confirmation that the patient is not using another GLP-1 receptor agonist at the same time.
Requests go through the NCTracks Provider Portal. NC Medicaid aims to decide prescription drug prior authorization requests within 24 hours. Expedited urgent requests are decided within 72 hours, and standard non-urgent requests may take up to 14 calendar days in some circumstances.
How Long Approval Lasts
Initial approval runs for six months. To renew, adults must show at least a 5% total weight loss from baseline, and adolescents must show a greater-than-4% reduction in baseline BMI. If those exact percentages are not met, the prescriber can document a clinically significant reduction as an alternative. There is no cap on the number of renewals.
The quantity limit for Wegovy is 3 mL per 28 days, or 2 mL per 28 days during dose titration.
Wegovy vs. Zepbound and Saxenda
Wegovy is the preferred GLP-1 for weight management, which matters if you or your prescriber would rather use a different drug. Zepbound (tirzepatide) and Saxenda (liraglutide) are both Non-Preferred Products. To get either approved, you generally have to try Wegovy first and have it fail, or your prescriber has to document a medical reason you cannot take it. Older non-GLP-1 weight-loss drugs, including phentermine, diethylpropion, and phendimetrazine, remain on the Preferred Drug List and do not require prior authorization.
Coverage for Non-Weight-Loss Uses
Wegovy is FDA-approved for two indications beyond weight management, and NC Medicaid covers both:
- Cardiovascular risk reduction in adults with established cardiovascular disease who have obesity or are overweight, an indication approved in March 2024.
- Treatment of noncirrhotic MASH (metabolic dysfunction-associated steatohepatitis) with moderate to advanced liver fibrosis in adults.
These are considered mandatory Medicaid benefits under federal law, which is why coverage for them continued even when weight-loss coverage was suspended in late 2025. The MASH indication has its own documentation requirements, including a FIB-4 fibrosis score and results from a liver biopsy, transient elastography, enhanced liver fibrosis score, or magnetic resonance elastography, and the prescription must be written by or in consultation with a hepatologist or gastroenterologist.
If Your Prior Authorization Is Denied
When a request is denied, both the provider and the beneficiary receive an adverse decision notice. The beneficiary has the right to appeal, and the notice explains how. For help, you can call the NC Medicaid Contact Center at 888-245-0179 (Monday through Friday, 8 a.m. to 5 p.m.) or the NCTracks Call Center at 800-688-6696. The clinical criteria your provider is working from are published on the NCTracks Pharmacy Prior Approval Drugs and Criteria page.
If you are enrolled in NC Medicaid Managed Care, the timing of system updates can vary by plan. The NC Medicaid website has a Health Plan Contacts and Resources page for plan-specific questions.
A Note on the 2025 Suspension
If you tried to fill a Wegovy prescription in late 2025 and were turned down, that was not permanent. On October 1, 2025, NC Medicaid discontinued coverage of Wegovy, Zepbound, and Saxenda for the treatment of obesity, citing “shortfalls in state funding.” Wegovy and Zepbound stayed available through prior authorization for their non-obesity indications during that stretch, but Saxenda was dropped entirely.
The suspension lasted about ten weeks. Governor Josh Stein directed DHHS to restore coverage, and the department announced reinstatement on December 19, 2025, with an effective date of December 12, 2025. The clinical criteria reverted to what had been in place as of September 30, 2025. If your prescription was denied during the suspension window, it is worth having your provider resubmit under the current criteria.